gefitinib has been researched along with phloretin in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (phloretin) | Trials (phloretin) | Recent Studies (post-2010) (phloretin) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 1,223 | 5 | 301 |
| Protein | Taxonomy | gefitinib (IC50) | phloretin (IC50) |
|---|---|---|---|
| Estrogen receptor | Homo sapiens (human) | 0.3 | |
| Sodium/hydrogen exchanger 9B2 | Homo sapiens (human) | 90 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dokuni, R; Kiriu, T; Kobayashi, K; Kunimasa, K; Nagano, T; Nishimura, Y; Satouchi, M; Shimono, Y; Tachihara, M; Tamura, D; Tokunaga, S; Yamamoto, M | 1 |
1 other study(ies) available for gefitinib and phloretin
| Article | Year |
|---|---|
Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cellular Senescence; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Glucose; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neoplastic Stem Cells; Phloretin; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Withanolides; Xenograft Model Antitumor Assays | 2017 |